Abstract: An agricultural machine applies liquid material to a field. Valve control signals control valves to apply the liquid material. Row pressure on the agricultural machine is sensed to identify when the valve is opened to apply the liquid material. The valve control signals are generated, based on the row pressure, to control the valves to apply the liquid material at a desired location in the field, relative to plant locations in the field.

Abstract: An apparatus for controlling docking with a spacecraft includes at least one camera for generating at least one image pixel stream of the spacecraft. A field programmable gate array (FPGA) receives the at least one image pixel stream from the at least one camera. The FPGA texture processes the at least one pixel stream to generate at least one texture map for the at least one image pixel stream. A processor receives the at least one texture map from the FPGA and calculates texture map statistics responsive to the generated at least one texture map, generates thresholding results for the at least one pixel image stream responsive to the generated at least one texture map, determines a bus centroid of the spacecraft responsive to the generated thresholding results and outputs the determined bus centroid of the spacecraft. A docking controller controls docking of with the spacecraft responsive to the determined bus centroid of the spacecraft.

Abstract: An assembly may be provided that includes a controller configured to be coupled with at least one blower drive that operates a blower motor to cool resistive elements that dissipate electrical power as heat. The controller may be configured to determine whether the electrical power is no longer received by the resistive elements and operate the at least one blower drive to operate the blower motor to cool the resistive elements responsive to the electrical power no longer being received by the resistive elements.

Abstract: The present invention relates to a method of purifying whole HCV particles, the method comprising the steps of a) providing a cell culture supernatant comprising virus particles, b) purification and/or concentration of the cell culture supernatant, c) purification and/or concentration of the product of above step b) using steric exclusion chromatography (SXC) at alkaline pH in the range of 8-10, d) purification and/or concentration of the product of above step c) using sulphated cellulose membrane absorbers (SCMA), e) obtaining purified whole virus particles.

Abstract: In a first aspect, the present invention relates to a method for the purification of virus compositions as well as biological macromolecular compounds in a sample comprising mixing the sample with osmolytes, like non-ionic organic polymers and contacting the mixed sample with a hydrophilic membrane, optionally washing the membrane, and eluting the virus preparations or biological macromolecular components from the membrane with an eluting solution containing reduced amounts or no osmolytes, like non-ionic organic polymer. Moreover, virus compositions and biological macromolecular components obtainable with the method according to the present invention are provided as well as the use of the method according to the present invention for purification of virus compositions including whole virus particles and virus-like particles or biological macromolecular components.

Abstract: Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase comprises the additive and an active agent dissolved therein, the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate proportional to the amount of active agent in the biphasic layer.

Abstract: The present invention relates to the use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase includes the additive and an active agent dissolved therein. The additive has a higher affinity to water than to the active agent and controls the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate being proportional to the amount of active agent in the biphasic layer.

Abstract: The present invention relates to a transdermal therapeutic system, comprising (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, wherein the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer, a kit comprising two transdermal therapeutic systems of the present invention as well as a method for the preparation of the transdermal therapeutic system of the present invention.

Abstract: The present invention relates to a transdermal therapeutic system formed from (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, in which the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer; a kit containing two transdermal therapeutic systems of the present invention; and methods for the preparation of the transdermal therapeutic system of the present invention. The present invention further relates to methods of treatment based upon the application of the inventive transdermal therapeutic systems once or twice weekly via systems adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.

Abstract: The invention relates to a fastening assembly (3) for fastening a test device holder (5) to a force measuring apparatus (1), having a test device holder (5) and a slide part (7) which can be or is arranged on a force measurement tower (9) of the force measuring apparatus (1) in such a way that the slide part can move in the vertical direction of the force measurement tower (9). The test device holder (5) has at least one position defining element (11), and the slide part (7) has at least one counter position defining element (13).

Abstract: The invention relates to a force measuring arrangement (3) in particular for applying a test parameter to a specimen and/or for measuring a resistance force applied by the specimen, having at least one force absorption element (25), a first fastening device and a force transmission element (27), wherein the force absorption element (25) can be fastened to a force measuring device in a movable manner by means of the first fastening device, wherein the force absorption element (25) is designed to measure a relative force acting between two force absorption regions, namely a first force absorption region and a second force absorption region (51), wherein the first fastening device is able to be connected to the force absorption element (25) in a force-transmitting manner via the first force absorption region, wherein the second force absorption region (51) is able to be connected to the force transmission element (27) in a force-transmitting manner by means of a second fastening device, wherein the force transmi

Abstract: The invention relates to a fastening arrangement (3) for fastening a sample holder (7) to a force measuring device (1), having a sample holder (7), and a counterpart holder (5) on the side of the force measuring device, which is formed or arranged on the force measuring device (1) or is fixedly connectable to the force measuring device (1), wherein the counterpart holder (5) has at least one sample holder receptacle (19, 21), wherein the sample holder (7) has a planar abutment surface (39) and the sample holder receptacle (19, 21) has a flat counterpart abutment surface (23), wherein the sample holder (7) furthermore has at least one positioning element (41, 43) and one fixing element (45), and the sample holder receptacle (19, 21) has at least one counterpart positioning element (25, 27) and one counterpart fixing element (29), wherein the positioning element (41, 43) and the counterpart positioning element (25, 27) are configured to uniquely define a relative position between the sample holder (7) and th

Abstract: Disclosed herein are a casino game as well as the methods and apparatus for conducting the game. In one embodiment, the Pokerlette™ game includes a game table or surface (physical or virtual) on which wagering and steps of the game are carried out using playing cards to implement the game as a combination of poker and roulette.

Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a nom-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

Abstract: A system can include a memory to store machine readable instructions. The system can also include a processing unit to access the memory and execute the machine readable instructions. The machine readable instructions can include a scheduling agent that can determine a download time for selected media content from a content provider. The download time can be based on a viewing time and a monitored network usage pattern over an extended period of time at the system.

Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

Abstract: In a first aspect, the present invention relates to a method for the purification of virus compositions as well as biological macromolecular compounds in a sample comprising mixing the sample with osmolytes, like non-ionic organic polymers and contacting the mixed sample with a hydrophilic membrane, optionally washing the membrane,and eluting the virus preparations or biological macromolecular components from the membrane with an eluting solution containing reduced amounts or no osmolytes, like non-ionic organic polymer. Moreover, virus compositions and biological macromolecular components obtainable with the method according to the present invention are provided as well as the use of the method according to the present invention for purification of virus compositions including whole virus particles and virus-like particles or biological macromolecular components.

Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.